Evaluation of Procedural And Clinical Outcomes With Transcatheter Aortic Valve Implantation: A Single-Center Experience
Open Access
- 1 January 2020
- journal article
- research article
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 23 (5), 288-296
- https://doi.org/10.14744/anatoljcardiol.2020.03942
Abstract
Objective: Transcatheter aortic valve implantation (TAVI) is an established alternative to surgical aortic valve replacement. Our study aimed to evaluate the implementation of TAVI at our large-volume center, having an all-comer patient population with short and long-term follow-ups. Methods: This retrospective, single-center analysis included 556 consecutive patients with symptomatic severe aortic stenosis (AS) who underwent TAVI between July 2011 and December 2019. Results: The mean age of the entire population was 77.6 +/- 7.9 years, and 54.9% were women. The Society of Thoracic Surgeons (STS) mean score of the cohort was 6.0%+/- 3.5%. The balloon-expandable valve (Sapien XT, Sapien 3; Edwards Lifesciences, Irvine, California) was the most frequently used valves in this cohort (94.6%). Transfemoral access was used in 96.3% of patients. Implantation success was achieved in 96.6% of cases. During the TAVI procedure, 7.2% of patients required permanent pacemaker implantation, with 37.5% in the Lotus valve group needing the most permanent pacemakers. The mean length of hospital stay for the entire cohort was 4.5 +/- 2.3 days. Overall, 22 (3.9%) in-hospital deaths occurred before hospital discharge. The mean follow-up period was 15.1 +/- 14.9 months for all patients, and a significant improvement was noted in all echocardiographic parameters and functional capacity. Paravalvular leak (PVL) was documented in 18.9% patients, mild in 17.9%, and moderate in 1% at discharge. No cases with severe PVL, necessitating additional procedures. The multiple logistic regression analysis revealed that sex, STS score, baseline SYNTAX score, bicuspid valve morphology, common femoral artery diameter, and post-TAVI PVL were independent predictors of overall mortality. Conclusion: To our knowledge, this study, which is the largest single-center real-world experience of TAVI in Turkey, demonstrated low complication rates with favorable short- and mid-term THV performance in patients undergoing TAVI.Keywords
This publication has 23 references indexed in Scilit:
- Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk PatientsNew England Journal of Medicine, 2016
- Comparison of EuroSCORE II, Original EuroSCORE, and The Society of Thoracic Surgeons Risk Score in Cardiac Surgery PatientsThe Annals of Thoracic Surgery, 2016
- Paravalvular Regurgitation After Transcatheter Aortic Valve ReplacementJACC: Cardiovascular Interventions, 2016
- Conduction Abnormalities and Pacemaker Implantations After SAPIEN 3 Vs SAPIEN XT: Depending on Who Is Implanted and How You Implant. ResponseRevista Española de Cardiología (English Edition), 2016
- Annual Outcomes With Transcatheter Valve TherapyJournal of the American College of Cardiology, 2015
- Transcatheter Aortic Valve Implantation in the United KingdomCirculation, 2015
- Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document†European Heart Journal, 2012
- EuroSCORE IIEuropean Journal of Cardio-Thoracic Surgery, 2012
- Transcatheter aortic valve implantationCatheterization and Cardiovascular Interventions, 2011
- Percutaneous Transcatheter Implantation of an Aortic Valve Prosthesis for Calcific Aortic StenosisCirculation, 2002